Preclinical In Vitro Efficacy Testing

A single large 3D tumoroid with ECM from a 96-well plate.

Improve Clinical Translation with Advanced in vitro Efficacy Testing

The development of oncology drugs is costly and plagued by a high attrition rate, underscoring the need for improved preclinical models to enhance clinical translation.

Carcinotech addresses this challenge with its patient-derived models, which preserve the complexity and heterogeneity of cancer while delivering a more representative immune response.

Innovate and Succeed: Partner with Carcinotech for Preclinical Research

Reduce Reliance on Animal Models

Comply with regulatory requirements by minimizing the use of animal models in your efficacy studies.

Improve Planning for Clinical Trials

Enhance trial success by identifying and stratifying patient cohorts most likely to respond to your therapy.

Optimize Therapeutic Translation

Bridge the gap from lab to clinical trials with enhanced accuracy and reliability.

Extend Your Scientific Capabilities

Collaborate with our scientific team for expert study design, assay development, and data analysis support.

How we Support Your Preclinical Study

At study onset, our expert team collaborates with you to define objectives and determine the necessary insights to drive actionable conclusions.

Source

We source tumor biopsies of specific types and subtypes on your behalf, guaranteeing alignment with your therapeutic focus.

Print

Our bioprinting methodologies create precise replicas of the patient tumor, optimized for high-throughput screening. This enables a highly relevant and efficient platform for efficacy testing.

Assess

We offer flexible options for your assessments: you can receive our models for self-conducted evaluations, or alternatively, our expert team can conduct assays on your behalf, tailored to your needs.

Explore our Services Further

Discover our end-to-end services designed to help you succeed.

Biopsy Sourcing

3D Tumor Development

Oncology Assays

In vitro Preclinical Testing Case Study

Discover a real-world example of our work supporting a European pharmaceutical organization.

Problem

Organization required drug efficacy evaluation for an immunotherapeutic targeting NSCLC patients with a rare mutation, present in only 15% of the NSCLC population.

Solution

Carcinotech sourced 13 patient samples and bioprinted 2 x 96-well plates per patient, ensuring accurate mutation representation in each sample.

Result

Organization received precision-focused drug efficacy data for their specific cancer mutation, accelerating preclinical testing by 1 year.

Enhance Preclinical Drug Testing Today

Ready to improve your preclinical study with human in vitro models? Contact us today to learn how our solution can support your drug development journey.

Move to Clinical Trials with Confidence